Fosrenol

What Is Fosrenol and What Is It Used For?

Fosrenol (lanthanum carbonate) is a phosphate binder prescribed to lower high phosphate levels in the blood (hyperphosphataemia) in adult patients with chronic kidney disease. It works locally in the gut by binding dietary phosphate, forming insoluble complexes that are excreted in the faeces rather than absorbed into the bloodstream.

In healthy individuals, the kidneys play a central role in maintaining phosphate balance by filtering excess phosphate from the blood and excreting it in the urine. When kidney function declines – as in chronic kidney disease (CKD) stages 3–5, and particularly in patients on dialysis – the kidneys lose their ability to adequately remove phosphate. This leads to a progressive build-up of phosphate in the blood, a condition known as hyperphosphataemia.

Elevated blood phosphate levels have serious clinical consequences. Hyperphosphataemia stimulates the release of parathyroid hormone (PTH), contributing to secondary hyperparathyroidism and a condition broadly referred to as chronic kidney disease–mineral and bone disorder (CKD-MBD). This complex syndrome involves abnormalities in calcium, phosphate, PTH, and vitamin D metabolism, leading to weakened bones (renal osteodystrophy), increased fracture risk, and – most critically – vascular calcification, where calcium-phosphate deposits accumulate in blood vessel walls and heart valves.

Vascular calcification is a major contributor to the exceptionally high cardiovascular mortality observed in patients with CKD. Clinical studies have consistently shown that elevated serum phosphate is an independent risk factor for cardiovascular events and death in dialysis patients. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines therefore recommend maintaining serum phosphate levels within the normal range, using a combination of dietary phosphate restriction, adequate dialysis, and phosphate-binding medications.

Fosrenol contains the active substance lanthanum, a rare earth element that has a strong affinity for phosphate ions. When taken with meals, lanthanum carbonate dissociates in the acidic environment of the stomach, releasing trivalent lanthanum ions (La³⁺). These ions bind to dietary phosphate across the full range of gastrointestinal pH values (pH 1–7), forming highly insoluble lanthanum phosphate complexes. Because these complexes cannot be absorbed through the intestinal wall, phosphate is effectively trapped and eliminated from the body in the faeces.

What Should You Know Before Taking Fosrenol?

Before starting Fosrenol, tell your doctor about all your medical conditions, particularly any gastrointestinal disorders, liver disease, or history of bowel surgery. Fosrenol is contraindicated in patients with hypophosphataemia (low phosphate) or bowel obstruction.

Contraindications

You should not take Fosrenol if any of the following apply to you:

• Allergy to lanthanum carbonate hydrate or any of the other ingredients in Fosrenol – symptoms of an allergic reaction may include rash, itching, swelling, or difficulty breathing
• Hypophosphataemia (low blood phosphate levels) – Fosrenol is designed to lower phosphate levels and could reduce them to dangerously low levels if phosphate is already low
• Bowel obstruction (intestinal blockage) – Fosrenol acts in the gastrointestinal tract and could worsen a physical blockage of the intestine

Warnings and Precautions

Talk to your doctor or pharmacist before taking Fosrenol if you have or have had any of the following conditions:

• Cancer of the stomach or intestine – gastrointestinal malignancies may alter drug absorption and tolerability
• Inflammatory bowel disease, including ulcerative colitis or Crohn's disease – the gastrointestinal effects of Fosrenol may exacerbate symptoms in patients with active inflammatory bowel disease
• Previous abdominal surgery, or peritonitis (infection or inflammation of the abdominal lining) – altered gut anatomy may affect how Fosrenol distributes and acts in the gastrointestinal tract
• Peptic ulcer disease (stomach or duodenal ulcers) – there is a theoretical risk of local irritation from the drug in areas of compromised mucosal integrity
• Reduced bowel motility, including severe constipation or diabetic gastroparesis – slowed gastrointestinal transit may increase the risk of intestinal obstruction, a known rare complication of phosphate binders
• Liver impairment – although lanthanum has negligible systemic absorption, biliary excretion is the primary route for any absorbed lanthanum, so hepatic impairment could theoretically alter elimination

If you have impaired kidney function (which is expected in patients taking this medication), your doctor may periodically check your blood calcium levels. If your calcium levels become too low (hypocalcaemia), you may be given calcium supplements to correct this.

Pregnancy and Breastfeeding

Fosrenol should not be used during pregnancy. The safety of lanthanum carbonate in pregnant women has not been established, and there are insufficient data to assess potential risks to the developing foetus. If you are pregnant, think you might be pregnant, or are planning to become pregnant, consult your doctor before taking Fosrenol. Your doctor will discuss alternative phosphate-lowering strategies that have a better-established safety profile during pregnancy.

It is not known whether lanthanum passes into breast milk. Although systemic absorption of lanthanum is negligible (<0.002%), breastfeeding is not recommended while taking Fosrenol as a precautionary measure. If you are breastfeeding, discuss the risks and benefits with your doctor before taking this medication.

Driving and Operating Machinery

Dizziness and vertigo (a sensation of spinning) have been reported as uncommon side effects in patients taking Fosrenol. If you experience these symptoms, you should not drive or operate heavy machinery until they have resolved. You are responsible for assessing your own fitness to drive. Discuss any concerns about these effects with your doctor or pharmacist.

Glucose Content

Fosrenol contains glucose (as dextrates). If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medicine. The amount of glucose per dose is small, but patients with diabetes should be aware of this excipient. Your doctor can advise you on whether this is clinically significant for your individual situation.

How Does Fosrenol Interact with Other Drugs?

Fosrenol can reduce the absorption of several medications when taken at the same time, including certain antibiotics, antifungals, antimalarials, and thyroid hormones. To avoid interactions, these drugs must be taken at specified intervals before or after Fosrenol. Always inform your doctor about all medications you are taking.

Fosrenol works by binding substances in the gastrointestinal tract. While its primary target is dietary phosphate, it can also bind to certain medications, reducing their absorption and effectiveness. This is a class effect seen with phosphate binders in general. The key to managing these interactions is timing – separating the administration of Fosrenol and the interacting drug by an appropriate interval.

Unlike many medications, Fosrenol has negligible systemic absorption and is not metabolised by cytochrome P450 (CYP) liver enzymes. This means it does not cause the hepatic drug-drug interactions that are common with many other medicines. Its interactions are purely local, occurring in the gastrointestinal tract through direct binding.

Major Interactions

Moderate Interactions

As a general rule, if you are taking any other medications, discuss the optimal timing with your doctor or pharmacist. Many CKD patients take multiple medications, and a careful administration schedule is essential to ensure that all drugs are absorbed properly. Your healthcare team can help you create a personalised medication timetable.

What Is the Correct Dosage of Fosrenol?

The typical starting dose of Fosrenol is 750 mg per day (250 mg three times daily with meals), which your doctor will adjust based on your blood phosphate levels. The dose may be increased every 2–3 weeks. The maximum recommended daily dose is 3000 mg. Your total daily dose is divided across your main meals.

Always take Fosrenol exactly as your doctor has prescribed. Do not change your dose without first consulting your doctor. The dose of Fosrenol depends on two key factors: the amount of phosphate in your diet and your current blood phosphate level. Your doctor will monitor your serum phosphate regularly and adjust the dose accordingly.

Chewable Tablets

Oral Powder Sachets

Before switching to the oral powder formulation, many patients will have started on chewable tablets at a lower dose so that their doctor can find the optimal dose through gradual titration. The chewable tablets are available in 250 mg, 500 mg, 750 mg, and 1000 mg strengths, allowing for fine dose adjustments.

Children

Fosrenol is not recommended for children and adolescents under 18 years of age. There is insufficient clinical data to establish the safety and efficacy of lanthanum carbonate in paediatric patients. If a child or adolescent with CKD requires phosphate-binding therapy, the doctor will prescribe an alternative agent with established paediatric data.

Elderly Patients

No specific dose adjustment is required for elderly patients. However, as elderly patients may be more susceptible to gastrointestinal side effects, your doctor may choose a more gradual dose titration approach. Serum phosphate and calcium levels should be monitored regularly, as with all patients taking Fosrenol.

Dietary Considerations

Fosrenol works by binding phosphate from your food. If you significantly change your diet – for example, by eating more or less protein-rich foods (which are typically high in phosphate) – your Fosrenol dose may need to be adjusted. Contact your doctor if you make major changes to your eating habits, as you may need a higher or lower dose to maintain adequate phosphate control.

Missed Dose

If you forget to take Fosrenol with a meal, simply take your next dose with your next meal. Do not take a double dose to make up for the forgotten one. Remember that Fosrenol is only effective when taken with food, so there is no benefit in taking a missed dose between meals.

Overdose

What Are the Side Effects of Fosrenol?

The most common side effects of Fosrenol are gastrointestinal, including nausea, vomiting, diarrhoea, and abdominal pain, which affect more than 1 in 10 people. These symptoms are most common at the start of treatment and typically improve over time. Constipation, which can rarely progress to bowel obstruction, requires medical attention.

Like all medicines, Fosrenol can cause side effects, although not everybody gets them. Most side effects are related to the gastrointestinal tract, which is expected since Fosrenol acts locally in the gut. Taking Fosrenol with or immediately after food – rather than before meals – can significantly reduce the risk of nausea and vomiting.

Frequency not known: Drug residues visible in the gastrointestinal tract during endoscopy or on imaging studies. This is not harmful and is expected due to the physical properties of lanthanum.

If you experience any side effects not listed here, or if any side effect becomes severe or persistent, contact your doctor or pharmacist. Reporting suspected side effects after the medicine has been authorised allows ongoing monitoring of the medicine's benefit-risk balance.

How Should You Store Fosrenol?

Store Fosrenol at room temperature, out of the reach and sight of children. No special storage conditions are required. Do not use after the expiry date on the packaging.

No special storage conditions are required for Fosrenol chewable tablets or oral powder sachets. Keep the medicine in its original packaging until ready to use. For the oral powder, do not open the sachet until you are ready to take the dose.

Check the expiry date on the carton and sachet/blister before each use. The expiry date refers to the last day of the stated month. Do not use Fosrenol after this date.

Do not dispose of unused medicines by flushing them down the toilet or putting them in household waste. Return any unused or expired medication to your pharmacy for safe disposal. This helps protect the environment from pharmaceutical contamination.

What Does Fosrenol Contain?

Fosrenol contains the active substance lanthanum (as lanthanum carbonate hydrate). Each chewable tablet or oral powder sachet is available in multiple strengths. The inactive ingredients include dextrates, colloidal anhydrous silica, and magnesium stearate.

Active Ingredient

The active substance is lanthanum, provided as lanthanum carbonate hydrate. Each dose unit contains lanthanum carbonate hydrate equivalent to the stated amount of lanthanum:

• Chewable tablets: 250 mg, 500 mg, 750 mg, or 1000 mg lanthanum
• Oral powder sachets: 750 mg or 1000 mg lanthanum

Inactive Ingredients (Excipients)

The other ingredients in the oral powder are: dextrates (hydrated), which serve as a carrier and sweetening agent; colloidal anhydrous silica, which acts as a flow agent; and magnesium stearate, which is used as a lubricant. These are standard pharmaceutical excipients that ensure the powder mixes evenly and has acceptable taste and texture.

Physical Description and Packaging

Oral powder: White to off-white powder supplied in individual sachets. The sachets are packaged in a carton containing 90 sachets (the outer carton contains 9 inner cartons of 10 sachets each).

Chewable tablets: White to off-white, round tablets of varying sizes depending on strength. They are scored to allow splitting where needed.

How Does Fosrenol Work in the Body?

Fosrenol works locally in the gastrointestinal tract, not systemically. Lanthanum ions bind dietary phosphate to form insoluble lanthanum phosphate, which passes through the gut and is excreted in the faeces. Less than 0.002% of lanthanum is absorbed into the body, making systemic side effects extremely unlikely.

The mechanism of action of Fosrenol is fundamentally different from most medications, which work by being absorbed into the bloodstream and distributed throughout the body. Fosrenol is a non-absorbed, locally acting agent that exerts its therapeutic effect entirely within the gastrointestinal tract.

When Fosrenol is taken with a meal, the chewed tablet or mixed powder encounters the acidic environment of the stomach. Lanthanum carbonate hydrate dissociates, releasing trivalent lanthanum ions (La³⁺). These positively charged ions have an extremely high affinity for phosphate anions (PO₄³⁻), which carry a strong negative charge. The resulting bond forms lanthanum phosphate (LaPO₄), an insoluble and chemically stable compound that cannot cross the intestinal epithelium.

One of the key advantages of lanthanum carbonate over older phosphate binders is its ability to bind phosphate effectively across a wide range of pH values (pH 1–7). This means the drug works in the acidic stomach, the neutral duodenum, and the slightly alkaline small intestine, providing comprehensive phosphate binding throughout the entire upper gastrointestinal tract where dietary phosphate is absorbed.

Pharmacokinetic Profile

The systemic bioavailability of lanthanum following oral administration is extremely low, less than 0.002%. This negligible absorption is a deliberate design feature of the drug, as its therapeutic action is entirely local. Any lanthanum that is absorbed is primarily eliminated via biliary excretion (through the bile into the faeces), with minimal renal excretion. The plasma elimination half-life is approximately 53 hours, but this is clinically irrelevant given the negligible amounts absorbed.

Because lanthanum is not metabolised by cytochrome P450 enzymes and does not enter the systemic circulation in meaningful amounts, it does not cause the pharmacokinetic drug-drug interactions that are common with hepatically metabolised drugs. Its drug interactions are purely based on physical binding in the gastrointestinal lumen, making them predictable and manageable through dose separation.

Long-term safety studies have shown that lanthanum does accumulate in bone tissue over time, although at very low concentrations. Clinical data from studies lasting up to 6 years have not demonstrated adverse effects on bone histology, turnover, or mineralisation associated with this accumulation. Nonetheless, ongoing monitoring is recommended, and the prescribing physician should regularly reassess the need for continued treatment.

Frequently Asked Questions About Fosrenol